Introduction
============

Hepatotoxicity is a significant adverse event in drug-induced liver injury (DILI). Cholestasis represents a frequent manifestation of DILI in humans, and it has an important function during the pathologic process. It is characterized by impaired hepatocellular secretion of bile and results in the accumulation of bile acids (BAs), bilirubin, and cholesterol in the liver^[@bib1]^. In many cases, cholestasis is due to alterations in hepatobiliary transporter system, particularly the sodium taurocholate co-transporting polypeptide (Ntcp or Slc10a1) and the bile salt export pump (Bsep or Abcb11), which are the most essential transporters of BA^[@bib2]^. The hepatic uptake and efflux of BAs are also mediated by other transporters, such as the organic anion transporting polypeptide (Oatp) and the multidrug resistance-associated protein 2 (Mrp2), which are responsible for taking up conjugated and unconjugated BAs into hepatocytes and pumping divalent BAs into the bile canaliculi, respectively^[@bib3],[@bib4]^.

Timosaponin A3 (TA3, [Figure 1A](#fig1){ref-type="fig"}), one of the major steroidal saponin components isolated from *Anemarrhena asphodeloides*, displays promising pharmacological activity in improving learning, memory, and antineoplastic activity^[@bib5],[@bib6]^. Our group recently found that TA3 had a very high concentration in rat liver after a single oral administration^[@bib7]^, and in an acute toxicity study, rat liver showed extensive ballooning degeneration and vacuolization ([Figure S1](#sup1){ref-type="supplementary-material"}). This acute toxicity may prevent the efforts to develop TA3 into a drug candidate if the mechanism of toxicity remains unclear. Although *Anemarrhena asphodeloides* and its extractions have been widely used medically for thousands of years, there have been no reports of its hepatoxicity^[@bib8]^. Additionally, no previous studies have detailed the toxicity of the *Anemarrhena asphodeloides* extract in rats. To assess the significance of this observation and understand the mechanism of potential liver damage induced by TA3, we examined the connections between TA3-induced hepatotoxicity and cholestasis.

Transporters play a critical role in cholestasis; our group has reported that toxicants may induce cholestasis by inhibiting BA transporter functions in sandwich-cultured rat hepatocytes (SCRHs)^[@bib9]^. The same strategy was employed here to investigate the hepatotoxicity of TA3.

In the present study, we investigated the cholestatic effect of TA3 in rats and SCRHs. The impact of TA3 on essential transporters and the integrity of hepatocytes was assessed. The protective role of antioxidants NAC and mangiferin (one of the active compounds of *Anemarrhena asphodeloides*) against TA3-induced oxidative stress in hepatocytes was also examined.

Materials and methods
=====================

Reagents and chemicals
----------------------

TA3 (purity ≥97%) and mangiferin (purity ≥95%) were extracted and purified at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, China). All other chemicals used were purchased from Sigma-Aldrich. All the reagents used in cell culture were obtained from GIBCO, unless otherwise stated.

Rat hepatocyte isolation and culture
------------------------------------

Rat hepatocytes were obtained via a two-step collagenase digestion method with modification^[@bib10]^. In brief, cell viability was \>85%, as determined by trypan blue exclusion. Isolated hepatocytes were seeded in culture plates coated with collagen-I and allowed to attach for 4 h in an incubator at 37 °C with 5% CO~2~ before the medium was changed. After 24 h, cells were overlaid with 0.25 mg/mL Matrigel (Palo Alto, CA, USA) in FBS-free, ice-cold medium. A sandwich configuration was formed during the following culture period as previously described^[@bib11]^. All the following cell experiments were conducted using the sandwich culture system at 24 h after coating with Matrigel, unless otherwise stated.

WST-1 assay
-----------

Hepatocytes were seeded in 96-well plates (3×10^4^ cells/well). Cultured hepatocytes were treated with TA3 (0--100 μmol/L) for 24 h. Cytotoxicity assays were performed after drug administration according to the WST-1 protocol (Beyotime, Haimen, China).

Reactive oxygen species (ROS) assay
-----------------------------------

Intracellular ROS production was assessed by the cellular conversion of DCFDA to 2′,7′-dichlorofluorescin (DCF)^[@bib12]^. After incubation with TA3 or TA3+NAC/mangiferin for 24 h, the medium was aspirated, and the hepatocytes (in a black 96-well microplate) were preloaded with 5 μmol/L DCFDA (dissolved in HBSS) and incubated for 1 h. After the incubation period, the cells were washed once with PBS, and the fluorescence intensity was measured using a multi-well fluorescence plate reader (Biotek, Winooski, USA) with excitation and emission wavelengths at 485 and 530 nm, respectively.

ATP assay
---------

ATP levels in hepatocytes were determined using a CellTiter-Glo^TM^ Luminescent Cell Viability Assay kit according to the manufacturer\'s instructions (Promega, Madison, WI, USA). Bioluminescence was measured by a microplate reader (Biotek, Winooski, USA).

Measurement of mitochondrial membrane potential (MMP)
-----------------------------------------------------

The MMP was monitored using tetramethylrhodamine ethylester (TMRE, 1 μmol/L), a red-orange dye, according to methods described previously^[@bib13]^. CCCP (20 μmol/L), a mitochondrial toxin, was used as a positive control^[@bib14]^. CCCP was added to the control samples 15 min before adding TMRE. After incubation for 20 min with TMRE, the cells were washed once with 0.2% BSA in PBS, and fluorescence readings were obtained on a microplate reader (Biotek, Winooski, USA) with excitation and emission wavelengths of 549 and 575 nm, respectively.

BA (d8-TCA) uptake and biliary excretion in SCRHs
-------------------------------------------------

The uptake and biliary clearance of deuterium-labeled sodium taurocholate (d8-TCA, Martrex, Inc, Minnesota, USA) in SCRHs were determined according to the method described previously^[@bib15]^ with slight modification. In brief, after incubation with TA3 or TA3+NAC for specific times (15 min, 2 h, and 24 h), SCRHs were rinsed two times with 300 μL of warm standard HBSS or Ca^2+^-free HBSS and pre-incubated with 300 μL of the same buffer at 37 °C for 15 min. After removing the buffer, the hepatocytes were incubated for 15 min with d8-TCA (1 μmol/L) in 300 μL of standard HBSS. After incubation, the solution was aspirated from the cells, uptake was terminated by washing three times with ice-cold PBS, and the samples were frozen for analysis. The biliary excretion index (BEI) was calculated as follows: BEI=\[*A*~HBSS~--*A*~HBSS~ (Ca^2+^free)\]/*A*~HBSS~×100%, which was defined as the proportion of accumulated taurocholate excreted into bile canaliculi^[@bib16]^, where *A*~HBSS~ and *A*~HBSS~ (Ca^2+^-free) represent the amount of accumulated d8-TCA in the standard buffer treatment wells (hepatocytes+bile) and calcium-free buffer treatment wells (hepatocytes), respectively.

BA (d8-TCA) accumulation in freshly isolated rat hepatocytes
------------------------------------------------------------

BA accumulation assays were performed as previously described^[@bib17],[@bib18]^ with slight modifications. Isolated hepatocytes were plated in 24-well plates. Once attached (4 h), the cells were washed twice with warmed standard HBSS (Na^+^ condition) or Na^+^-free choline buffer (10 mmol/L Tris, 5 mmol/L glucose, 5.4 mmol/L KCl, 1.8 mmol/L CaCl~2~, 0.9 mmol/L MgSO~4~, 10 mmol/L HEPES, and 137 mmol/L choline). Subsequently, the hepatocytes were incubated with the uptake buﬀer for 10 min. After aspiration of the pre-incubation buffer, taurocholate uptake was initiated by the addition of 300 μL of standard HBSS or Na^+^-free choline buffer containing d8-TCA and TA3 at 37 °C for 15 min. Troglitazone (10 μmol/L) was selected as the positive control, as it inhibits d8-TCA uptake^[@bib18]^. Finally, the accumulation of d8-TCA was terminated by washing the hepatocytes two times with ice-cold PBS, and the samples were frozen for analysis.

Gene expression measured by quantitative RT-PCR
-----------------------------------------------

After the treatment of TA3 or TA3+NAC in SCRHs for 24 h, total RNA was isolated from the hepatocytes with TRIzol reagent (Life Technology, CA, USA), and RNA was reverse-transcribed to cDNA using a Primescript RT Reagent Kit (Takara, Shiga, Japan). Gene expression levels were quantified using a real-time PCR kit (Qiagen, Hilden, Germany). Primers for the *Cyp7a1*, *Bsep*, *Mrp2*, *Ntcp*, and β-*actin* genes were synthesized with the sequences listed in [Table 1](#tbl1){ref-type="table"}. β-Actin was used for internal normalization. The genes of interest were amplified using a Qiagen Roter Gene Q instrument (Qiagen).

Animal study
------------

Male Sprague-Dawley (SD) rats (200±20 g) were obtained from the Shanghai Laboratory Animal Center Co, Ltd (Shanghai, China). The animals were housed in an air-conditioned room with a 12-h on and 12-h off light cycle, and they received powdered rodent chow and tap water by the bottle *ad libitum*. Experiments were approved by the Institutional Animal Care and Use Committee of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

The rats were used to isolate hepatocytes and for the following animal studies. During drug treatment, TA3 was suspended in a 0.5% carboxymethylcellulose sodium solution (CMC-Na^+^) and administered by oral gavage in a volume of 10 mL/kg body weight at dose levels of 100 mg/kg for fourteen consecutive days. The controls received the same volume of vehicle. After the final administration of TA3 or vehicle, the rats were fasted overnight and anesthetized with pentobarbital. Blood samples were collected from oculi chorioideae vein, and a polyethylene tube (Clay Adams, USA) was then inserted into the common bile duct for bile collection. All of the samples were stored at -80 °C until analysis.

Blood biochemistry
------------------

Serum for biochemistry analysis was obtained from rat blood samples. Alanine aminotransferase (ALT) and total BA (TBA) were determined using an Automatic Clinical Analyzer (7080, HITACHI Ltd, Tokyo, Japan).

Analysis of biological samples
------------------------------

The d8-TCA concentration in hepatocytes was analyzed by liquid chromatography-mass spectrometry tandem mass spectrometry (LC-MS/MS) (LCMS-8030; Shimadzu, Kyoto, Japan)^[@bib9]^. The data were normalized to the protein amount using a BCA protein assay (Rockford, IL, USA). The analysis of bile samples was performed on an Agilent 1290 Infinity UPLC coupled to an Agilent 6460 Triple-Quadrupole mass spectrometer equipped with a JetStream^TM^ ESI source (Agilent Technologies, Inc, Santa Clara, CA, USA) according to a previous report^[@bib19]^.

Confocal microscopy
-------------------

F-actin was stained with phalloidin-FITC^[@bib20]^ using a previously described method^[@bib21]^. In brief, hepatocytes were seeded onto glass cover slips, fixed in 3% (*w/v*) formaldehyde for 20 min, washed three times using PBS, and permeabilized by soaking the coverslips in 0.1% (*v/v*) Triton X-100 in PBS for 5 min. After washing three times in PBS, the cover slips were treated with a 5 μg/mL solution of FITC-phalloidin in PBS for 20 min. The cover slips were washed three times in PBS and mounted in 90% glycerol-PBS containing 2.5% (*w/v*) diazabicyclo\[2,2,2\]octane. The specimens were examined using laser-scanning fluorescence microscopy.

Western blotting
----------------

The total protein of hepatocytes was extracted by RIPA lysis buffer containing 1 mmol/L phenylmethylsulfonyl fluoride (Beyotime, Haimen, China). The proteins were separated by 8% SDS-PAGE. After transferring the proteins to a polyvinylidene difluoride membrane, the membrane was blocked, incubated with primary antibodies overnight at 4 °C, washed, incubated with HRP-labeled secondary antibodies for 1 h, washed again, and visualized using an enhanced chemiluminescence detection system (Millipore, USA). β-Actin was selected as the internal control.

Statistical analysis
--------------------

Data are presented as the mean±SD. Statistical analysis was performed using GraphPad Prism 5.03 software. Differences between the two groups were analyzed using Student\'s *t*-test. A one-way ANOVA and Tukey\'s multiple comparison test were used to test statistical significance among groups. Differences were considered significant at *P*\<0.05.

Results
=======

TA3 induced hepatotoxicity *in vitro* and cholestasis *in vivo*
---------------------------------------------------------------

SCRHs were exposed to TA3 for 24 h in a 96-well plate, and cell viability was determined by the WST-1 assay. It was found that TA3 reduced cell viability in a dose-dependent manner ([Figure 1B](#fig1){ref-type="fig"}), and the IC~50~ was 15.21±1.73 μmol/L. Based on this result, in the following *in vitro* experiments, we used the concentration of TA3 below the IC~50~.

Male rats were administered 100 mg/kg TA3 daily for fourteen consecutive days (the dosage is 10% of the LD~50~, data not shown). Body weight loss was observed ([Figure S2A](#sup1){ref-type="supplementary-material"}), and the TBA and ALT in the serum of TA3-fed rats increased significantly compared with that in the vehicle-fed group ([Figure 2A](#fig2){ref-type="fig"} and [Figure S2B](#sup1){ref-type="supplementary-material"}). The measured concentrations of BA constituents (CA, TCA, GCA, GCDCA, CDCA, TCDCA, TDCA, and DCA) in bile decreased compared with those in the vehicle group after 14 d of TA3 administration ([Figure 2B](#fig2){ref-type="fig"}).

D8-TCA uptake and efflux in hepatocytes after TA3 treatment
-----------------------------------------------------------

After acute TA3 treatment (15 min), the uptake and BEI of d8-TCA in hepatocytes did not change significantly ([Figure 3A](#fig3){ref-type="fig"}, [3B](#fig3){ref-type="fig"}, and [Table 2](#tbl2){ref-type="table"}). The uptake of d8-TCA in primary rat hepatocytes was assessed through the presence or absence of Na^+^ ([Figure 3A](#fig3){ref-type="fig"}, [3B](#fig3){ref-type="fig"}). The accumulation of d8-TCA in hepatocytes was not impeded by TA3 in either case.

After 2 and 24 h of incubation with TA3, the accumulation and biliary excretion of d8-TCA in SCRH significantly decreased ([Figure 3C](#fig3){ref-type="fig"}, [3D](#fig3){ref-type="fig"}, and [Table 2](#tbl2){ref-type="table"}). The decrease in d8-TCA accumulation and biliary excretion after 24 h of TA3 treatment was greater than the reduction after 2 h.

Effect of TA3 on BA-related transporters and synthesizing enzyme expression in SCRHs
------------------------------------------------------------------------------------

TA3 significantly decreased the mRNA levels of the influx transporter Ntcp and efflux transporters Bsep and Mrp2. The BA-synthesizing enzyme Cyp7a1 was also downregulated by TA3 ([Figure 4A--4D](#fig4){ref-type="fig"}). Western blot analysis showed that the expression levels of Bsep and Cyp7a1 decreased ([Figure 4E](#fig4){ref-type="fig"}).

ROS generation and hepatotoxicity in TA3-treated SCRHs
------------------------------------------------------

The ROS level of TA3-treated hepatocytes significantly increased compared with the vehicle-treated control hepatocytes ([Figure 5A](#fig5){ref-type="fig"}). The expression of oxidative stress-related genes (heme oxygenase 1, HO-1) in SCRHs dose-dependently increased after 24 h of TA3 treatment ([Figure 5B](#fig5){ref-type="fig"}). Compared with the TA3-treated cells, the amount of ROS generated in the TA3+NAC- or TA3+mangiferin-treated hepatocytes was significantly reduced. The ROS production level was almost declined to those in TA3 untreated controls ([Figure 5C](#fig5){ref-type="fig"}, [5E](#fig5){ref-type="fig"}). The results of the ATP assay also indicated that NAC and mangiferin reduced TA3-induced cytotoxicity ([Figure 5D](#fig5){ref-type="fig"} and [Figure S3B](#sup1){ref-type="supplementary-material"}). A loss in MMP was observed in SCRHs treated with 5 and 10 μmol/L TA3 for 12 h; however, NAC pretreatment restored the MMP to normal levels ([Figure 5F](#fig5){ref-type="fig"}).

mRNA expression of Ntcp, Bsep, Mrp2, and Cyp7a1 in SCRHs treated with TA3 and NAC
---------------------------------------------------------------------------------

RT-PCR analysis demonstrated that the expression levels of the *Ntcp*, *Bsep*, *Mrp2*, and *Cyp7a1* genes in response to TA3+NAC treatment were higher than those in SCRHs following TA3 treatment alone ([Figure 6](#fig6){ref-type="fig"}). Mrp2 expression nearly recovered to the level of the control group after co-incubation with NAC. The expression level of the Cyp7a1 gene considerably decreased compared with that of control even in the presence of NAC.

Assessment of BA basolateral transporter function in SCRHs treated with TA3 and NAC
-----------------------------------------------------------------------------------

The effect of NAC on d8-TCA uptake in SCRHs treated with TA3 was determined. The amounts of d8-TCA in SCRH were only 47.1%±6.0% and 24.2%±6.1% of those in the vehicle-treated control at 2 and 24 h (respectively) after TA3 treatment. NAC co-incubation with TA3 increased the d8-TCA concentrations in SCRHs to 57.0%±11.0% and 43.1%±2.2% at 2 and 24 h, respectively ([Figure 7A](#fig7){ref-type="fig"}, [7B](#fig7){ref-type="fig"}).

The function of BA biliary excretion was also verified. The reduction in d8-TCA efflux activity by TA3 was time-dependent. In [Figure 7C](#fig7){ref-type="fig"}, the BEI of d8-TCA decreased by 29.0% after 2 h of TA3 treatment (BEI values decreased from 82.1%±2.2% to 58.1%±5.0%). The reduction decreased to 12.5% (BEI values: 74.3%±2.2% to 65.0%±2.5%) in the presence of NAC. When the incubation time was extended to 24 h, the BEI decreased by 36.0% (BEI values: 86.0%±6.2% to 54.9%±6.0%) in the TA3-treated group, whereas the BEI only slightly decreased by 9.0% (BEI values: 77.8%±5.4% to 71.0%±9.5%) when NAC was added ([Figure 7D](#fig7){ref-type="fig"}). This finding indicated that NAC could improve the function of BA canalicular membrane transporters impaired by TA3.

Disruption of the hepatocyte cytoskeleton protein F-actin after TA3 treatment in SCRHs
--------------------------------------------------------------------------------------

The effect of TA3 on F-actin in SCRHs was investigated. Upon TA3 treatment, the structure of the actin cytoskeleton was distinctly blurred compared with that in the vehicle control group, indicating F-actin disruption after TA3 treatment ([Figure 8A](#fig8){ref-type="fig"}, [8B](#fig8){ref-type="fig"}). By contrast, when hepatocytes were co-treated with TA3 and NAC, the actin cytoskeleton partly recovered ([Figure 8C](#fig8){ref-type="fig"}), and the cells displayed normal cell morphology. This result suggests that NAC protected F-actin against TA3-induced disruption.

Discussion
==========

BA homeostasis (including both synthesis and transporting processes) is strictly regulated in hepatocytes, which is critical to the maintenance of hepatocyte function. Interfering in these homeostatic mechanisms may lead to BA-induced hepatotoxicity^[@bib22],[@bib23]^. Drug-induced cholestatic liver injury may be related to the direct inhibition of BA transporters (Ntcp and Bsep)^[@bib2],[@bib24]^. Many laboratories have studied the mechanism of drug-induced cholestasis and have focused on the inhibition potency on BA transporters by a number of drugs, such as nefazodone^[@bib25]^, ritonavir, and saquinavir^[@bib15]^, all of which induce cholestasis and liver injury.

In the present study, inconsistent with the suggested safe use of *Anemarrhena asphodeloides*, we found that after a 14-day treatment of TA3 in rats, the levels of TBA and ALT in serum increased significantly ([Figure 2A](#fig2){ref-type="fig"} and [Figure S2B](#sup1){ref-type="supplementary-material"}). The analysis of the BA profile in bile ([Figure 2B](#fig2){ref-type="fig"}) suggested that the blockage of the excretion of BA could lead to the increase in BA in the blood and the disturbance of BA in the liver, which confirmed the preliminary observation that TA3 may produce cholestasis and potential liver injury.

The SCRH model was employed to interpret our *in vivo* observations. SCRHs are a valuable tool for evaluating metabolic enzyme- and hepatobiliary transporter-based hepatotoxicity^[@bib26]^ because of their proper three-dimensional orientation and localization of important efflux transporters, such as Mrp2 and Bsep^[@bib27],[@bib28]^. In SCRHs, BA could be taken into hepatocytes by Ntcp and Oatps and excreted into bile canaliculi by Bsep and Mrp2. After a 15 min treatment with TA3, there were no changes observed in the uptake and biliary excretion of d8-TCA (a stable isotope of BA). Given that Ntcp is responsible for the majority of BA uptake and this process is Na^+^-dependent, (Oatp transport of BA is Na^+^-independent)^[@bib29]^, we compared the impact of Na^+^ on d8-TCA accumulation during TA3 treatment. It was found that TA3 had no effect on d8-TCA uptake in rat hepatocytes, regardless of the presence of Na^+^ ([Figures 3A](#fig3){ref-type="fig"}, [3B](#fig3){ref-type="fig"}). These results indicated that TA3 was not a potent inhibitor of BA transporters. TA3 did not induce BA elevation by directly inhibiting BA uptake or efflux transporters.

However, if TA3 was incubated with hepatocytes for 2 or 24 h, the accumulation and biliary excretion of d8-TCA decreased significantly ([Figures 3C](#fig3){ref-type="fig"}, [3D](#fig3){ref-type="fig"}, and [Table 2](#tbl2){ref-type="table"}). This suggested that TA3 time- and dose-dependently impaired the function of BA transporters in hepatocytes. It was reported that if xenobiotics interfere with BA transporters and enzyme expression, that normal BA homeostasis may be disturbed^[@bib2]^. Therefore, we determined the impact of TA3 on the expression of BA-related genes Ntcp, Bsep, Mrp2, and Cyp7a1. A significant decrease in the expression of these genes was observed in SCRHs ([Figures 4A--4D](#fig4){ref-type="fig"}). The extent of the reduction of Ntcp was much greater than that of Bsep, suggesting that TA3 had a greater effect on BA uptake transporters than efflux transporters. This may lead to the decreased accumulation of BA. Mrp2 is responsible for mediating the excretion of divalent BAs and bilirubin^[@bib22]^ and plays an important role in conjugated hyperbilirubinemia^[@bib30]^. Mrp2 mRNA expression was also reduced by TA3, suggesting that it may contribute to TA3-induced cytotoxicity as well. The decrease in Cyp7a1 at both the gene and protein levels was considered to be negative feedback regulation following the reduction of BA accumulation in hepatocytes because CYP7a1 is the rate-limiting step in BA biosynthesis^[@bib31]^.

Oxidative stress is often critical in drug-induced hepatotoxicity^[@bib32],[@bib33],[@bib34]^. Our study revealed that TA3 treatment induced ROS generation in SCRHs and upregulated HO-1 gene expression, which is associated with the oxidative stress pathway ([Figures 5A](#fig5){ref-type="fig"}, [5B](#fig5){ref-type="fig"}). The excess production of ROS can oxidize proteins, DNA, lipids, and other macromolecules, thereby leading to the disruption of cell processes and hepatocyte injury^[@bib35],[@bib36]^. NAC reduced ROS production and restored ATP levels and MMP in TA3-treated hepatocytes ([Figures 5C](#fig5){ref-type="fig"}, [5D](#fig5){ref-type="fig"}, and [5F](#fig5){ref-type="fig"}). These results confirmed the role of oxidative stress in TA3-induced hepatotoxicity.

Mangiferin is one of the active compounds in *Anemarrhena asphodeloides*^[@bib37],[@bib38]^, and the amount in the herb is greater than that of TA3. In our study, 10 μg/mL (approximately 25 μmol/L) mangiferin completely restored the TA3-induced ROS generation and the ATP and LDH changes to normal levels in hepatocytes ([Figure 5E](#fig5){ref-type="fig"} and [Figure S3B](#sup1){ref-type="supplementary-material"}). Not even NAC showed such an impressive protective effect on TA3-induced hepatotoxicity at this dose. This may be the key factor in explaining why no liver injury cases have been found after previous *Anemarrhena asphodeloides* treatment in the clinic.

Membrane transporters can be internalized by acute oxidative stress^[@bib39],[@bib40]^, but there has been no direct connection reported between oxidative stress and liver transporter interruption in drug-induced cholestasis. It was previously reported that Ntcp could be internalized in the liver by taurochenodeoxycholate (TCDC); however, this process was not attributed to ROS^[@bib41]^. For the same reason, it has been noted that oxidative stress may lead to cholestasis, but there was no connection between ROS and BA transporter expression^[@bib42],[@bib43]^. In this study, the reduced expression levels of Ntcp, Bsep, and Mrp2 in SCRH were increased by NAC ([Figure 6](#fig6){ref-type="fig"}). The uptake and biliary excretion function of SCRH was also restored in the presence of NAC ([Figure 7A--7D](#fig7){ref-type="fig"}). These results implied that NAC or other antioxidants may increase the expression of BA transporters that have been reduced by drug-induced oxidative stress. This is the direct evidence in SCRHs that oxidative stress may lead to the disruption of polarized transporter systems in hepatocytes. By contrast, Cyp7a1 expression was still very low and could not be recovered by NAC, which implies that oxidative stress is not the only reason for TA3-induced cholestasis in the liver.

F-actin cytoskeletal integrity is required for the normal localization of transporters at the canalicular membrane domain^[@bib44],[@bib45]^. It was reported that oxidative stress may induce the actin cytoskeleton and tight junction alterations in hepatocytes^[@bib46]^. When the hepatocytes were treated with TA3, the pre-canalicular staining of F-actin became irregular and "fuzzy," reflecting significant disruption. By contrast, the disruption of pre-canalicular F-actin was partly prevented in the TA3+NAC-treated cells ([Figure 8](#fig8){ref-type="fig"}). This could be another consequence of oxidative stress caused by the TA3 treatment.

In conclusion, our research explored the potential mechanisms of TA3-induced cholestasis and hepatotoxicity from a novel perspective: the connections between oxidative stress and liver transporter interruption. Using sandwich-cultured rat hepatocytes, our study revealed that TA3 does not inhibit BA transporters directly; however, TA3 may disrupt the polarization of the BA transporter system by generating ROS in hepatocytes. The antioxidants NAC and mangiferin effectively protected hepatocytes against TA3-induced cytotoxicity by attenuating oxidative stress. This study identified the connections between oxidative stress and liver transporter interruption in SCRHs.
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Body weight (A) and serum biochemistry (ALT) (B) were measured after TA3 treatment for 14 days.
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![The chemical structure of TA3 and TA3-induced cytotoxicity. (A) The chemical structure of TA3. (B) Cell viability in sandwich-cultured rat hepatocytes (SCRHs) after TA3 treatment. The hepatocytes were treated with TA3 or vehicle for 24 h. The data are presented as the mean±SD (*n*=6).](aps201465f1){#fig1}

![TA3-induced cholestasis and disrupted bile acids homeostasis in SD rats. (A) Changes in total BA levels in serum after TA3 administration at 100 mg/kg daily for 14 d. (B) The determination of 8 types of BA components (CA, TCA, GCA, GCDCA, CDCA, TCDCA, TDCA, and DCA) in bile. The data are presented as the mean±SD (*n*=4--6). ^b^*P*\<0.05, ^c^*P*\<0.01 *vs* vehicle.](aps201465f2){#fig2}

![The effects of TA3 on the accumulation of d8-TCA in freshly isolated rat hepatocytes and SCRHs. D8-TCA (1 μmol/L) uptake by rat hepatocytes at 15 min, 37 °C, co-incubated with TA3 (5, 10, 20, and 50 μmol/L) in Na^+^-added (A) and Na^+^-free (B) buffer. Troglitazone (10 μmol/L) was used as a positive control. SCRHs were incubated with d8-TCA (1 μmol/L) for 15 min after TA3 (1, 5, and 10 μmol/L) treatment for 2 h (C) and 24 h (D), and the concentration of d8-TCA was measured. The data are presented as the mean±SD (*n*=4). ^b^*P*\<0.05, ^c^*P*\<0.01 *vs* vehicle.](aps201465f3){#fig3}

![The mRNA and protein levels of genes involved in BA transport and synthesis measured by RT-PCR and Western blot analysis after TA3 (1, 5, and 10 μmol/L) treatment for 24 h. The expression levels of each gene were expressed as values normalized to β-actin expression. (A) Ntcp mRNA expression; (B) Bsep mRNA expression; (C) Mrp2 mRNA expression; (D) Cyp7a1 mRNA expression; (E) Expression of protein levels of Bsep and Cyp7a1. The data are presented as the mean±SD (*n*=3). ^b^*P*\<0.05, ^c^*P*\<0.01 *vs* vehicle.](aps201465f4){#fig4}

![The impact of NAC or mangiferin on TA3-induced hepatotoxicity in SCRHs. (A) The ROS level was measured after TA3 (5 and 10 μmol/L) treatment for 8 h. (B) Real-time PCR analysis of HO-1 expression in hepatocytes treated with TA3 (1, 5, and 10 μmol/L) for 24 h. Cells were pretreated with NAC (5 mmol/L) and co-incubated with TA3 (1, 5, 10, and 20 μmol/L), then the ROS level (C) and ATP level (D) was measured. (E) The ROS level after pretreatment with mangiferin (10, 50, and 200 μg/mL) and NAC (5 mmol/L) for 2 h and co-incubated with TA3 (10 μmol/L) for 24 h. (F) The MMP level after pretreatment with NAC (5 mmol/L) for 2 h and co-incubation with TA3 (10 μmol/L) for 12 h. CCCP (20 μmol/L) was used as a positive control. The data are presented as the mean±SD (*n*=5). ^b^*P*\<0.05, ^c^*P*\<0.01 compared with the control. ^e^*P*\<0.05, ^f^*P*\<0.01 (TA3+NAC/mangiferin treatment *vs* TA3 alone).](aps201465f5){#fig5}

![NAC improved the expression of BA transporters and the synthesizing gene. Hepatocytes were pretreated with NAC (5 mmol/L) and co-incubated with TA3 (5 μmol/L) for 24 h. Cell samples were collected to isolate total RNA, and the gene was determined by RT-PCR. The data are presented as the mean±SD (*n*=3). ^b^*P*\<0.05, ^c^*P*\<0.01 (TA3+NAC treatment *vs* TA3 alone).](aps201465f6){#fig6}

![Effects of NAC on d8-TCA uptake and efflux in TA3-treated SCRH. Cells were incubated with d8-TCA (1 μmol/L) after treatment with TA3+NAC for 2 h (A) and 24 h (B), and d8-TCA accumulation was determined. D8-TCA efflux capacity was calculated as the BEI of d8-TCA. (C) BEI of d8-TCA after treatment for 2 h. (D) BEI of d8-TCA after treatment for 24 h. The data are presented as the mean±SD (*n*=3). ^b^*P*\<0.05, ^c^*P*\<0.01 *vs* vehicle. ^e^*P*\<0.05, ^f^*P*\<0.01 (TA3+NAC treatment *vs* TA3 alone).](aps201465f7){#fig7}

![Phalloidin-FITC-labeled F-actin localization in SCRHs after treatment with DMSO (A), TA3 (5 μmol/L) (B), and TA3 (5 μmol/L)+NAC (5 mmol/L) (C) for 18 h. Pericanalicular F-actin was indicated by green fluorescence (20×magnification).](aps201465f8){#fig8}

###### Sequence of primers for RT-PCR analysis. F, forward; R, reverse.

  Gene         Sequence (5′--3′)       Size (bp)   GenBank accession
  ------------ ----------------------- ----------- -------------------
  *Mrp2* F     GAAGGCATTGACCCTATCT     318         NM_012833.1
  *Mrp2* R     CCACTGAGAATCTCATTCATG                
  *Bsep* F     ATGTTGGAACGGAGGAACTG    205         NM_031760.1
  *Bsep* R     CCTTCTCGACCCGATATTCA                 
  *Ntcp* F     AGGCATGATCATCACCTTCC    277         NM_017047
  *Ntcp* R     AAGTGGCCCAATGACTTCAG                 
  *Cyp7a1* F   CACCATTCCTGCAACCTTTT    170         NM_012942.2
  *Cyp7a1* R   GTACCGGCAGGTCATTCAGT                 
  *HO-1* F     CACGCATATACCCGCTACCT    227         NM_012580.2
  *HO-1* R     AAGGCGGTCTTAGCCTCTTC                 

###### Effect of TA3 on the biliary excretion index (BEI) of d8-TCA in SCRHs. Data are expressed as the percentage of the control. Mean±SD. *n*=3. ^b^*P*\<0.05, ^c^*P*\<0.01 compared with the control.

  Treatment time   TA3 (μmol/L)   BEI (%) of d8-TCA   \% of Control
  ---------------- -------------- ------------------- ---------------
  15 min           0              60.0±6.0            100
  1                60.6±7.8       101                 
  5                55.7±10.4      92                  
  10               56.6±2.0       95                  
  2 h              0              72.3±4.0            100
  1                71.5±6.0       99                  
  5                53.9±10.2^b^   75                  
  10               17.8±2.1^c^    25                  
  24 h             0              74.4±3.2            100
  1                64.7±4.3       87                  
  5                28.1±9.6^c^    38                  
  10               15.1±11.0^c^   20                  
